Singapore HSA — the 2026 therapeutic-products updates and where the supplement-to-therapeutic line moved.

The Health Sciences Authority's 2026 updates to the therapeutic-products guidance refine — meaningfully — the line that separates a Health Supplements Programme product from a therapeutic product subject to full HSA registration. The shift affects ingestible categories making structure-or-function claims that brush against indication language, several novel actives that have been operating in the supplement lane, and the longevity-adjacent SKUs that price and present like clinical products. Reclassification is not a marketing problem; it changes the dossier, the manufacturing standard required, and the post-market reporting commitments. Brands operating in this border zone should be prepared to either tighten their claims to remain HSP-eligible or commit to the registration pathway. The middle ground is no longer available.